April 18, 2017 / 6:09 AM / in 6 months

BRIEF-Cellnovo acquires commercial license for artificial pancreas technology

April 18 (Reuters) - Cellnovo Group SA:

* Cellnovo acquires commercial license for artificial pancreas technology from Typezero Technologies

* Integration and commercialization of Typezero’s artificial pancreas (ap) technology into Cellnovo’s mobile diabetes management systems.

* Integration efforts are currently underway with a product launch expected in 2018; no financial terms have been disclosed Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below